Biotech News

CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases

CRISPR Therapeutics (CRSP)CRISPR TherapeuticsCompany update

Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response Zugo-cel has been well tolerated in all 21 patients dosed to date, with no

Related news

CRSPCRISPR Therapeutics2026-10-02 14:15 EST

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

NTLAIntellia2026-11-12 15:00 EST

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

NTLAIntellia2026-11-03 13:00 EST

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

ABEOAbeona Therapeutics2026-09-18 11:30 EST

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

SRPTSarepta Therapeutics2026-09-30 12:30 EST

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

OCGNOcugen2026-11-10 12:00 EST

Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN

SRPTSarepta Therapeutics2026-10-26 20:30 EST

Sarepta Therapeutics to Present at Upcoming Investor Conferences

ABEOAbeona Therapeutics2026-08-13 11:30 EST

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

CRISPR Therapeutics

Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies. CASGEVY CASGEVY...

Recent company news

Stock data

Close
38.93 USD
Market cap
5.02B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States